{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:43:28Z","timestamp":1759754608233,"version":"build-2065373602"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["429175970"],"award-info":[{"award-number":["429175970"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Vaccination with tumor-(neo) antigen plus adjuvant is emerging as a promising cancer-therapy. However, as different adjuvants induce distinct immune cell and antibody (Ab) responses, selecting the right adjuvants remains challenging. Here, we evaluated the following vaccine adjuvants to promote protection against tumor-growth in mice and correlated IgG subclass and Fc <jats:italic>N<\/jats:italic>-glycosylation responses: Alum; the toll-like receptor activators Poly(I:C) and MPLA; Alum-Poly(I:C); and the more inflammatory water-in-oil adjuvants Montanide, IFA, CFA, and <jats:italic>M.tb.<\/jats:italic>-enriched (e)CFA. While Alum and Montanide failed to protect, MPLA and IFA tended to protect, and Poly(I:C), Alum-Poly(I:C), CFA, and eCFA significantly protected against tumor-growth. Across all adjuvants, tumor-protection correlated with the induction of highly activating IgG2(c\/b) Abs and afucosylated (F0) IgG1 Abs, the latter showing up to 5% abundance. While all adjuvants transiently induced IgG1 F0 following initial immunization, Poly(I:C)- and eCFA-induced memory responses also generated IgG1 F0 after repeated antigen-exposure without adjuvants. Additionally, Poly(I:C)-induced tumor-protection was associated with high IgG2c\/IgG1 ratios, high levels of IgG galactosylation and sialylation, and IFN\u03b3-producing CD8\u2009+\u2009Tc1-cells. Conversely, Ova-eCFA-induced tumor-protection was additionally associated with high levels of IgG across all subclasses, but low levels of galactosylation and sialylation, and CD8\u2009+\u2009Tc17- and CD4\u2009+\u2009Th17-cells. Accordingly, tumor protecting adjuvants may induce common but also different protecting programs. A tumor-antigen-specific IgG2a monoclonal (m)Ab protected against tumor-growth in both its de-galactosylated and galactosylated plus sialylated forms, suggesting common and possibly distinct protective mechanisms. Tumor-protection via serum transfer from Poly(I:C)-immunized mice depended more on NK-cells, whereas eCFA-induced and non-sialylated\/non-galactosylated mAbs promoted neutrophil activation. These findings may help to improve tumor vaccination protocols.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1186\/s40164-025-00708-6","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:08:34Z","timestamp":1759752514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-tumor vaccine efficacy depends on adjuvant type and associates with induced IgG subclass and glycosylation profiles"],"prefix":"10.1186","volume":"14","author":[{"given":"Selina","family":"Lehrian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wasynczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janina","family":"Petry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Guderian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Nouta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana Sophia","family":"Buhre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna B.","family":"Lunding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"K\u00f6cher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah Franziska","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"D\u00fchring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Kurwahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Manzhula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannic C.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Wuhrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"4","key":"708_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2.PMID:33473220.Review","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329. https:\/\/doi.org\/10.1038\/s41571-020-00460-2.PMID:33473220.Review.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5753","key":"708_CR2","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1126\/science.1118948","volume":"310","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510\u20132. https:\/\/doi.org\/10.1126\/science.1118948.","journal-title":"Science"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3389\/fimmu.2018.00958","volume":"9","author":"G-M Lilienthal","year":"2018","unstructured":"Lilienthal G-M, Rahm\u00f6ller J, Petry J, Bartsch YC, Leliavsky A, Ehlers M. Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fcgamma receptor activation pathways. Front Immunol. 2018;9:958. https:\/\/doi.org\/10.3389\/fimmu.2018.00958.","journal-title":"Front Immunol"},{"issue":"1","key":"708_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4049\/jimmunol.1700116","volume":"199","author":"CW Bruggeman","year":"2017","unstructured":"Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell Fc\u03b3 receptor profile. J Immunol. 2017;199(1):204\u201311. https:\/\/doi.org\/10.4049\/jimmunol.1700116.","journal-title":"J Immunol"},{"key":"708_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.molimm.2017.12.006","volume":"94","author":"G Dekkers","year":"2018","unstructured":"Dekkers G, Bentlage AEH, Plomp R, Visser R, Koeleman CAM, Beentjes A, et al. Conserved Fc\u03b3R- glycan discriminates between fucosylated and afucosylated IgG in humans and mice. Mol Immunol. 2018;94:54\u201360. https:\/\/doi.org\/10.1016\/j.molimm.2017.12.006.","journal-title":"Mol Immunol"},{"issue":"3","key":"708_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/abt\/tbab016","volume":"4","author":"C Mao","year":"2021","unstructured":"Mao C, Near R, Zhong X, Gao W. Cross-species higher sensitivities of Fc\u03b3RIIIA\/Fc\u03b3RIV to afucosylated IgG for enhanced ADCC. Antib Ther. 2021;4(3):159\u201370. https:\/\/doi.org\/10.1093\/abt\/tbab016.","journal-title":"Antib Ther"},{"issue":"1","key":"708_CR7","doi-asserted-by":"publisher","first-page":"2430295","DOI":"10.1080\/19420862.2024.2430295","volume":"16","author":"T Cviji\u0107","year":"2024","unstructured":"Cviji\u0107 T, Horvat M, Plahutnik J, Golob A, Maru\u0161i\u010d J. Multivariate quantitative analysis of glycan impact on IgG1 effector functions. MAbs. 2024;16(1):2430295. https:\/\/doi.org\/10.1080\/19420862.2024.2430295.","journal-title":"MAbs"},{"issue":"7","key":"708_CR8","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","volume":"184","author":"DJ DiLillo","year":"2010","unstructured":"DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184(7):4006\u201316. https:\/\/doi.org\/10.4049\/jimmunol.0903009.","journal-title":"J Immunol"},{"issue":"3","key":"708_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jaci.2020.04.059","volume":"146","author":"YC Bartsch","year":"2020","unstructured":"Bartsch YC, Eschweiler S, Leliavski A, Lunding HB, Wagt S, Petry J, et al. IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants. J Allergy Clin Immunol. 2020;146(3):652-666.e11. https:\/\/doi.org\/10.1016\/j.jaci.2020.04.059.","journal-title":"J Allergy Clin Immunol"},{"issue":"87","key":"708_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104408","volume":"2023","author":"J Van Coillie","year":"2023","unstructured":"Van Coillie J, Pongracz T, Rahm\u00f6ller J, Chen H-J, Geyer C, van Vught LA, et al. in collaboration with the Fatebenefratelli-Sacco Infectious Diseases Physicians group and UMC COVID-19 S3\/HCW study group The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccines. EBioMedicine. 2023;2023(87):104408. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104408.","journal-title":"EBioMedicine"},{"key":"708_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8378","author":"MD Larsen","year":"2021","unstructured":"Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Nouta J, Hoepel W, et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science. 2021. https:\/\/doi.org\/10.1126\/science.abc8378.","journal-title":"Science"},{"key":"708_CR12","doi-asserted-by":"publisher","first-page":"1006939","DOI":"10.3389\/fimmu.2022.1006939","volume":"13","author":"JS Buhre","year":"2022","unstructured":"Buhre JS, Becker M, Ehlers M. IgG subclass and Fc glycosylation shifts are linked to the transition from pre- to inflammatory autoimmune conditions. Front Immunol. 2022;13:1006939. https:\/\/doi.org\/10.3389\/fimmu.2022.1006939.","journal-title":"Front Immunol"},{"issue":"4","key":"708_CR13","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1172\/JCI65579","volume":"123","author":"P Karagiannis","year":"2013","unstructured":"Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest. 2013;123(4):1457\u201374. https:\/\/doi.org\/10.1172\/JCI65579.","journal-title":"J Clin Invest"},{"issue":"1","key":"708_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cell.2019.05.044","volume":"178","author":"MF Jennewein","year":"2019","unstructured":"Jennewein MF, Goldfarb I, Dolatshahi S, Cosgrove C, Noelette FJ, Krykbaeva M, et al. Fc glycan-mediated regulation of placental antibody transfer. Cell. 2019;178(1):202-215.e14. https:\/\/doi.org\/10.1016\/j.cell.2019.05.044.","journal-title":"Cell"},{"issue":"9","key":"708_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.2862","volume":"18","author":"CM Karsten","year":"2012","unstructured":"Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc\u03b3RIIB and dectin-1. Nat Med. 2012;18(9):1401\u20136. https:\/\/doi.org\/10.1038\/nm.2862.","journal-title":"Nat Med"},{"issue":"18","key":"708_CR16","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1182\/blood-2013-04-497446","volume":"122","author":"M Albanesi","year":"2013","unstructured":"Albanesi M, Mancardi DA, J\u00f6nsson F, Iannascoli B, Fiette L, Di Santo JP, et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood. 2013;122(18):3160\u20134. https:\/\/doi.org\/10.1182\/blood-2013-04-497446.","journal-title":"Blood"},{"issue":"2","key":"708_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43018-023-00516-z.PMID:36806801.Review","volume":"4","author":"S Zinn","year":"2023","unstructured":"Zinn S, Vazquez-Lombardi R, Zimmermann C, Sapra P, Jermutus L, Christ D. Advances in antibody-based therapy in oncology. Nat Cancer. 2023;4(2):165\u201380. https:\/\/doi.org\/10.1038\/s43018-023-00516-z.PMID:36806801.Review.","journal-title":"Nat Cancer"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00708-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00708-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00708-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:08:34Z","timestamp":1759752514000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00708-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00708-6","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The murine studies were reviewed and approved by the Ethics Committee of the Ministry of Schleswig\u2013Holstein, Germany and performed in accordance with the approved protocol and other relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed on the final version of the article and submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}